Navigation Links
Stem cells central to pathogenesis of mature lymphoid tumors
Date:8/15/2011

New research suggests that blood stem cells can be involved in the generation of leukemia, even when the leukemia is caused by the abnormal proliferation of mature cells. The study, published by Cell Press in the August 16th issue of the journal Cancer Cell, may guide future strategies aimed at identifying therapeutic targets for chronic lymphocytic leukemia (CLL).

CLL is a cancer of a type of mature white blood cell called a B lymphocyte. "Most human CLL cases have a precursor phase, called monoclonal B lymphocytosis (MBL), that is an asymptomatic proliferation of B cells," explains senior study author Dr. Dr. Koichi Akashi from Kyushu University Graduate School of Medical Sciences in Japan. "Our question was, if progression from MBL to CLL reflects stepwise proliferation of aberrant cells, at what stage does the first cancer-causing event occur?"

To look for the cell population with cancer-initiating activity in human CLL, Dr. Akashi and colleagues tried to find the specific developmental stage where abnormal clonal B cells first appear. They began at the beginning, with hematopoietic stem cells (HSCs). HSCs are blood stem cells that can give rise to any type of blood cell. The researchers purified HSCs from healthy individuals or HSCs from CLL patients and transplanted them into mice with a deficient immune system. In contrast to the normal HSCs, the CLL HSCs gave rise to B cells similar to those seen in MBL. Interestingly, the CLL HSCs did not have chromosomal abnormalities common to CLL, suggesting that acquisition of chromosomal abnormalities that transform MBL into CLL are secondary events.

Taken together, the findings suggest that HSCs are involved in the pathogenesis of CLL, even though CLL is a malignancy of a mature cell type. "Our data suggest that the propensity to progress to CLL is already acquired at the HSC stage," concludes Dr. Akashi. "Identification of the intrinsic abnormality of HSCs in patients with CLL should be the key to finding the ultimate therapeutic target in human CLL."


'/>"/>

Contact: Lisa Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology news :

1. Gladstone scientists offer new insight into the regulation of stem cells and cancer cells
2. A novel mechanism that regulates pro-inflammatory cells is identified
3. Researchers use human cells to engineer functional anal sphincters in lab
4. Researchers gain new insights into how tumor cells are fed
5. Cells die so defensive organs can live
6. Disappearance of genetic material allows tumor cells to grow
7. Solar cells get a boost from bouncing light
8. NTU unveils new center to develop solar cells and clean energy systems of tomorrow
9. Could patients own kidney cells cure kidney disease?
10. Sea squirt cells shed light on cancer development
11. BUSM awarded $9 million to investigate treatment for sickle cell disease using iPS cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology: